Another retrospective study reported ORR 8.3% and median PFS 1.4 months in combined de novo exon 20 p.T790M mutant NSCLC patients receiving first-line treatment with first-generation EGFR TKIs [44]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.